Search results
Showing 316 to 330 of 1401 results for 0
Evidence summaries: new medicines – Interim process statement (PMG1)
This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
Epiretinal brachytherapy for wet age-related macular degeneration (HTG279)
Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.
View recommendations for HTG279Show all sections
Sections for HTG279
Evidence-based recommendations on percutaneous endoscopic laser cervical discectomy. This involves inserting special equipment, including a laser, through a small cut in the skin to heat and destroy some of the disc and remove the part that is sticking out to relieve pressure on the spinal cord or nerve root.
View recommendations for HTG194Show all sections
Sections for HTG194
Evidence-based recommendations on ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids in adults. This involves focusing high-intensity ultrasound energy at the fibroids through the skin of the abdomen.
View recommendations for HTG523Show all sections
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)
Evidence-based recommendations on spinal cord stimulation for chronic pain of neuropathic or ischaemic origin in adults.
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)
NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital .
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
This document summarises the most common accessibility changes NICE is making in guidelines, and why
Healthy start vitamins: special report on cost effectiveness (ECD5)
This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering